Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia

Anna Schuhmacher, Kai‐Uwe Kühn, Gabriela Cvetanovska, Dan Rujescu, Peter Zill, Boris B. Quednow, Marcella Rietschel, Wolfgang Wölwer, Wolfgang Gäebel, Michael Wagner,

Pharmacogenetics and Genomics · 2008 · 59 citations · 8 references

Concepts

Abstract

The serotonin (5-HT) 1A receptor has been found to be dysregulated in prefrontal cortex and other brain regions in schizophrenia, and 5-HT1A receptor levels in the amygdala have been related to negative schizophrenia symptoms. We have assessed the impact of the functional C-1019G variant of the 5-HT1A receptor on the response to risperidone or haloperidol in a prospective, randomized, double-blind study. Patients were treated for 4 weeks and negative symptoms assessed weekly. The variant influenced the response to risperidone: improvement of negative symptoms by 4.38 points for carriers of the C allele, compared with the GG genotype (1.22 points, P=0.046). In a second independent study of 130 schizophrenia patients treated with atypical antipsychotics, this effect was confirmed (P=0.003). The functional variant of the 5-HT1A receptor thus influences the response of schizophrenia patients to atypical antipsychotics and may be useful in the future to predict the pharmacogenetics of negative symptoms.

References

8